Mark Leschly Net Worth

Mark Leschly biography

Mark Leschly serves as Independent Director of the Company. Since July 1999, he has been a Managing Partner at Rho Capital Partners, Inc., an investment and venture capital management company. Since 2017, Mr. Leschly has been the Chairman and Chief Executive Officer of Universal Tennis, LLC, which is the developer of a software platform for tennis analytics and tournament management. Since 2014, Mr. Leschly has also been the owner and managing member of Iconica LLC, which primarily focuses on investments at the intersection of sports, media and technology. From 2002 to 2016, he was a member of the board of directors of Anacor Pharmaceuticals, Inc. Mr. Leschly also serves on the board of a number of private companies. Mr. Leschly received an A.B. from Harvard University and an M.B.A. from the Stanford Graduate School of Business.

What is the salary of Mark Leschly?

As the Independent Director of Ngm Biopharmaceuticals Inc, the total compensation of Mark Leschly at Ngm Biopharmaceuticals Inc is 221,618$. There are 11 executives at Ngm Biopharmaceuticals Inc getting paid more, with David Woodhouse having the highest compensation of 2,092,150$.

How old is Mark Leschly?

Mark Leschly is 51, he's been the Independent Director of Ngm Biopharmaceuticals Inc since 2018. There are 10 older and 5 younger executives at Ngm Biopharmaceuticals Inc. The oldest executive at Ngm Biopharmaceuticals Inc is David Goeddel, 68, who is the Lead independent director.

What's Mark Leschly's mailing address?

Mark's mailing address filed with the SEC is 152 WEST 57TH STREET, 23RD FLOOR, NEW YORK, NY, 10019.

Insiders trading at Ngm Biopharmaceuticals Inc

Over the last 5 years, insiders at Ngm Biopharmaceuticals Inc have traded over 9,159,599$ worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth 177,396,366$ . The most active insiders traders include Peter Svennilson、David V Goeddel、Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of 171,092$. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth 15,615$.

What does Ngm Biopharmaceuticals Inc do?

ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work

Ngm Biopharmaceuticals Inc executives and stock owners

Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include:

• David Woodhouse,
  Chief Executive Officer, Director
• Jin-Long Chen,
  Founder, Chief Scientific Officer, Director
• William Rieflin,
  Executive Chairman of the Board of Directors
• Suzanne Hooper,
  Independent Director
• Dr. David J. Woodhouse Ph.D.,
  CEO & Director
• Dr. Jin-Long Chen Ph.D.,
  Founder, Chief Scientific Officer & Director
• Shelly Guyer,
  Independent Director
• Siobhan Nolan Mangini,
  CFO and Principal Financial & Accounting Officer
• McHenry Tichenor,
  Independent Director
• David Goeddel,
  Lead independent director
• David Schnell,
  Independent Director
• Mark Leschly,
  Independent Director
• William J. Rieflin J.D.,
  Exec. Chairman of Directors
• Siobhan Mangini,
  Chief Financial Officer
• Carole Ho,
  Independent Director
• Hsiao Lieu,
  Senior Vice President, Chief Medical Officer
• Marc Learned,
  Vice President - Research Operations
• Hui Tian,
  Senior Vice President - Research
• Wenyan Shen,
  Senior Vice President - Biologics and CMC
• Alex DePaoli,
  Senior Vice President, Chief Translational Officer
• Valerie Pierce,
  Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
• Dr. Hsiao Dee Lieu,
  Chief Medical Officer & Sr. VP
• Brian Muma,
  VP of HR
• Valerie L. Pierce J.D.,
  Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer
• Alexander Duke Schwartz,
  Exec. Director of Investor Relations
• Group L Ptcg Opportunity Ii...,
  
• Group L Pcolumn Group Gp, L...,
  
• Group L Pcolumn Group Gp, L...,
  
• Group L P Svennilson Peter ...,
  
• Peter Svennilson,
  Director
• Group L Pcolumn Group Ii, L...,
  
• Group L Pcolumn Group Iii, ...,
  
• Aetna Wun Trombley,
  President & COO
• Group L Pcolumn Group Ii, L...,
  
• Group L Pcolumn Group Ii, L...,
  
• Group L P Ponoi Capital Ii,...,
  
• Group L Pcolumn Group Iii, ...,
  
• Roger M Perlmutter,
  
• Group L Pcolumn Group Gp, L...,
  
• Group L Pcolumn Group Iii, ...,
  
• Jean Frederic Viret,
  Chief Financial Officer
• Group Gp, Lpcolumn Group Ii...,
  
• Opportunity Iii Gp, Llc Tcg,
  10% owner
• Irene Perlich,
  Principal Accounting Officer